# Jos Caetano Villasboas-Bisneto

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 85 papers | 327 citations | 9 h-index | 17 g-index |
| 95 ext. papers | 526 ext. citations | 3.4 avg, IF | 3.39 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 85 | Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.. *Leukemia and Lymphoma*, **2022**, 1-6 | 1.9 | 0 |
| 84 | Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.. *Frontiers in Cell and Developmental Biology*, **2022**, 10, 752326 | 5.7 | 1 |
| 83 | Peak Absolute Lymphocyte Count After CAR-T Infusion Predicts Clinical Response in Aggressive Lymphoma.. *American Journal of Hematology*, **2022**, | 7.1 | 1 |
| 82 | Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.. *Journal of Hematology and Oncology*, **2022**, 15, 36 | 22.4 | 2 |
| 81 | Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.. *Leukemia and Lymphoma*, **2022**, 1-8 | 1.9 | |
| 80 | Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations. *JCO Oncology Practice*, **2021**, 17, e490-e496 | 2.3 | |
| 79 | Does Bridging Radiation Therapy Affect the Pattern of Failure After CAR T-cell Therapy in Non-Hodgkin Lymphoma?. *Radiotherapy and Oncology*, **2021**, | 5.3 | 5 |
| 78 | An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNENIS). *Blood*, **2021**, 138, 1333-1333 | 2.2 | |
| 77 | Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival Outcome in Aggressive Lymphoma. *Blood*, **2021**, 138, 3856-3856 | 2.2 | 0 |
| 76 | Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience. *Blood*, **2021**, 138, 3842-3842 | 2.2 | 1 |
| 75 | Central Nervous System Involvement By Mantle Cell Lymphoma. *Blood*, **2021**, 138, 2426-2426 | 2.2 | 0 |
| 74 | Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. *Blood*, **2021**, 138, 1750-1750 | 2.2 | |
| 73 | Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. *Blood*, **2021**, 138, 2518-2518 | 2.2 | |
| 72 | Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. *Blood*, **2021**, 138, 1373-1373 | 2.2 | |
| 71 | Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?. *Blood*, **2021**, 138, 2908-2908 | 2.2 | 0 |
| 70 | Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma. *Blood*, **2021**, 138, 3841-3841 | 2.2 | |
| 69 | Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. *Blood*, **2021**, 138, 3857-3857 | 2.2 | |

| | | | |
|---|---|---|---|
| 68 | Immunologic Autograft Engineering: 13 Years Follow-up. *Blood*, **2021**, 138, 3936-3936 | 2.2 | 0 |
| 67 | Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. *Blood*, **2021**, 138, 1439-1439 | 2.2 | |
| 66 | Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. *Blood*, **2021**, 138, 568-568 | 2.2 | 0 |
| 65 | Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. *Blood*, **2021**, 138, 2527-2527 | 2.2 | 1 |
| 64 | Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. *Blood Cancer Journal*, **2021**, 11, 65 | 7 | 1 |
| 63 | Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. *International Journal of Cancer*, **2021**, 149, 378-386 | 7.5 | 3 |
| 62 | Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. *European Journal of Haematology*, **2021**, 107, 48-53 | 3.8 | |
| 61 | Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. *Journal of Clinical Oncology*, **2021**, 39, e19501-e19501 | 2.2 | |
| 60 | Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.. *Journal of Clinical Oncology*, **2021**, 39, 7558-7558 | 2.2 | |
| 59 | Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. *Journal of Clinical Oncology*, **2021**, 39, e19547-e19547 | 2.2 | 0 |
| 58 | Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. *Journal of Clinical Oncology*, **2021**, 39, 7542-7542 | 2.2 | |
| 57 | Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. *Journal of Clinical Oncology*, **2021**, 39, 7530-7530 | 2.2 | |
| 56 | Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.. *Journal of Clinical Oncology*, **2021**, 39, 7554-7554 | 2.2 | 0 |
| 55 | Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?. *Journal of Clinical Oncology*, **2021**, 39, e19556-e19556 | 2.2 | 0 |
| 54 | Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.. *Journal of Clinical Oncology*, **2021**, 39, 7555-7555 | 2.2 | |
| 53 | Insurance status and survival in diffuse large B-cell lymphoma: A National Cancer Database study before and after the Affordable Care Act.. *Journal of Clinical Oncology*, **2021**, 39, 6539-6539 | 2.2 | |
| 52 | Outcomes in mantle cell lymphoma with central nervous system involvement.. *Journal of Clinical Oncology*, **2021**, 39, e19527-e19527 | 2.2 | 0 |
| 51 | The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.. *Journal of Clinical Oncology*, **2021**, 39, e19554-e19554 | 2.2 | |

| | | | |
|---|---|---|---|
| 50 | Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. *Blood Cancer Journal*, **2021**, 11, 133 | 7 | 1 |
| 49 | Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. *Blood Cancer Journal*, **2021**, 11, 130 | 7 | 5 |
| 48 | Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin lymphoma. *American Journal of Hematology*, **2021**, 96, E386-E389 | 7.1 | 3 |
| 47 | The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. *Blood Cancer Journal*, **2021**, 11, 124 | 7 | 0 |
| 46 | The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. *American Journal of Hematology*, **2021**, 96, E399-E402 | 7.1 | 3 |
| 45 | Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. *Hematological Oncology*, **2021**, 39, 658-663 | 1.3 | 1 |
| 44 | Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. *American Journal of Hematology*, **2021**, 96, E427-E430 | 7.1 | 0 |
| 43 | Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. *Blood Advances*, **2020**, 4, 5425-5430 | 7.8 | 10 |
| 42 | ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. *OncoImmunology*, **2020**, 9, 1744980 | 7.2 | 40 |
| 41 | Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. *American Journal of Hematology*, **2020**, 95, 1170 | 7.1 | 1 |
| 40 | Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. *British Journal of Haematology*, **2020**, 190, 79-83 | 4.5 | 0 |
| 39 | High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. *Blood*, **2020**, 136, 42-43 | 2.2 | |
| 38 | Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). *Blood*, **2020**, 136, 30-30 | 2.2 | 0 |
| 37 | The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. *Blood*, **2020**, 136, 23-25 | 2.2 | |
| 36 | Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. *Blood*, **2020**, 136, 21-21 | 2.2 | |
| 35 | Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2020**, 136, 42-43 | 2.2 | |
| 34 | Infused Autograft-Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched-Control Study. *Blood*, **2020**, 136, 8-9 | 2.2 | |
| 33 | Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. *Blood*, **2020**, 136, 36-37 | 2.2 | |

| | | | |
|---|---|---|---|
| 32 | High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. *Blood*, **2020**, 136, 17-18 | 2.2 | |
| 31 | Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. *Blood*, **2020**, 136, 7-8 | 2.2 | 2 |
| 30 | Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). *Blood*, **2020**, 136, 29-30 | 2.2 | 2 |
| 29 | Predictors of short-term survival in Waldenström Macroglobulinemia. *Leukemia and Lymphoma*, **2020**, 61, 2975-2979 | 1.9 | 1 |
| 28 | Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. *Blood Cancer Journal*, **2019**, 9, 72 | 7 | 21 |
| 27 | Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. *Leukemia Research*, **2019**, 81, 1-9 | 2.7 | 5 |
| 26 | The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. *American Journal of Hematology*, **2019**, 94, 658-666 | 7.1 | 9 |
| 25 | Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2019**, 9, 65 | 7 | 12 |
| 24 | SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. *Blood Cancer Journal*, **2019**, 9, 84 | 7 | 16 |
| 23 | A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). *Blood*, **2019**, 134, 4306-4306 | 2.2 | 3 |
| 22 | Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. *Blood*, **2019**, 134, 121-121 | 2.2 | 7 |
| 21 | Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. *Blood*, **2019**, 134, 4106-4106 | 2.2 | 4 |
| 20 | The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). *Blood*, **2019**, 134, 1591-1591 | 2.2 | 3 |
| 19 | Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. *Blood*, **2019**, 134, 1517-1517 | 2.2 | |
| 18 | Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. *Blood*, **2019**, 134, 2790-2790 | 2.2 | |
| 17 | Central Nervous System Involvement in Peripheral T-Cell Lymphoma. *Blood*, **2019**, 134, 5293-5293 | 2.2 | |
| 16 | Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. *Cell Reports*, **2019**, 26, 2178-2193.e3 | 10.6 | 37 |
| 15 | Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. *Blood*, **2018**, 132, 1879-1879 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 14 | Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely Recommendations. *Blood*, **2018**, 132, 618-618 | 2.2 | 1 |
| 13 | Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). *Blood*, **2018**, 132, 4138-4138 | 2.2 | |
| 12 | Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. *Blood*, **2018**, 132, 4344-4344 | 2.2 | |
| 11 | Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884 | 2.2 | 1 |
| 10 | Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib. *Case Reports in Oncology*, **2017**, 10, 726-731 | 1 | 3 |
| 9 | Glancing at the complex biology of T-cells through the microenvironment of Hodgkin lymphoma. *Leukemia and Lymphoma*, **2017**, 58, 1019-1021 | 1.9 | 1 |
| 8 | Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma. *Oncotarget*, **2017**, 8, 61425-61439 | 3.3 | 83 |
| 7 | Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. *Expert Review of Anticancer Therapy*, **2016**, 16, 5-12 | 3.5 | 12 |
| 6 | Initial presentation of CNS-restricted acute lymphoblastic B cell leukaemia as peripheral polyneuropathy. *BMJ Case Reports*, **2016**, 2016, 10.1136/bcr-2016-214645 | 0.9 | 1 |
| 5 | Signal-Regulatory Protein- (SIRP- ) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. *Blood*, **2016**, 128, 2515-2515 | 2.2 | |
| 4 | Recent advances in the management of Hodgkin lymphoma. *F1000Research*, **2016**, 5, | 3.6 | 4 |
| 3 | Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. *Cancer Journal (Sudbury, Mass )*, **2016**, 22, 17-22 | 2.2 | 13 |
| 2 | Therapeutic targets and investigated strategies for treating B-cell non-Hodgkin lymphoma. *Expert Opinion on Orphan Drugs*, **2015**, 3, 921-932 | 1.1 | |
| 1 | Multiparametric Analysis of Intra-Tumoral T-Cells in Hodgkin's Lymphoma Using Mass Cytometry (CyTOF). *Blood*, **2015**, 126, 1438-1438 | 2.2 | 1 |